CAMP4 Therapeutics
CAMP4 Therapeutics' revenue rose 436.5% to $4 million in fiscal 2025. Its operating margin was −1,502.4%, up from −8,142.3% a year earlier. Free cash flow was −$30 million. The diluted share count rose 547.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CAMP4 Therapeutics does
CAMP4 Therapeutics is a clinical-stage drug company with no approved products. It is developing a new type of medicine that targets regulatory RNAs, molecules that help switch genes on and off, with the aim of raising how much of a protein a gene makes and so treating genetic diseases. It finds these targets with its own discovery platform, called the RAP Platform.
Its lead candidate, CMP-002, is for SYNGAP1-related disorder, a severe childhood brain disease with seizures and developmental delay. There are no approved disease-modifying therapies for it. The company estimates that approximately 21,000 people have SYNGAP1 in the United States and the five largest European markets. CMP-002 has so far been tested in animals. The company has started toxicology studies and intends to begin a Phase 1/2 trial in people as early as the second half of 2026.
It has never made revenue from product sales and relies on raising money to fund its work.
Its biggest risks, as it describes them
- Having lost money since it began, with no approved products, and may never be profitable.
- Needing a lot more capital, and raising it could dilute owners or limit its operations.
- An unproven approach based on its RAP Platform that may not produce workable drugs.
- Early results in animals or early trials that may not predict later results.
- Low numbers of patients with the diseases it targets, making trials harder to fill.
Income statement
CAMP4 Therapeutics lost money in fiscal 2025: a net loss of $80 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 38 | 64 | 110 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 5.1x | 6.9x | 7.3x |
| Quick ratio | 5.1x | 6.9x | 7.3x |
Cash flow
Projections
Project CAMP4 Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $77,433 of CAMP4 Therapeutics shares on the open market, and 2 insiders sold $2.5 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Kelly GoldChief Financial Officer | Bought | 10,000 | $3.96 | $39,600 | Form 4 |
| Aug 27, 2026 | Andrew J. SchwabDirector | Sold | 400,000 | $4.04 | $1.6 million | Form 4 |
| Aug 24, 2026 | Andrew J. SchwabDirector | Sold | 10 | $4.50 | $45 | Form 4 |
| Aug 21, 2026 | Andrew J. SchwabDirector | Sold | 32,018 | $4.50 | $144,081 | Form 4 |
| Aug 20, 2026 | Andrew J. SchwabDirector | Sold | 114,700 | $4.54 | $520,738 | Form 4 |
| Aug 19, 2026 | Andrew J. SchwabDirector | Sold | 45,147 | $4.76 | $214,900 | Form 4 |
| Aug 19, 2026 | Daniel TardiffChief Scientific Officer | Sold | 1,738 | $4.76 | $8,273 | Form 4 |
| Aug 3, 2026 | Richard A YoungDirector | Bought | 16,378 | $1.65 | $27,024 | Form 4 |
| Aug 3, 2026 | Josh Mandel-BrehmChief Executive Officer, Director | Bought | 6,551 | $1.65 | $10,809 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −6,969.4% | −416.3% |
| Altman Z'' | −4.24 | −4.88 |
| Accruals ratio | −9.3% | −51.9% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Fail |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Pass |
| F-score | — | — |
Compare
Put CAMP4 Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CAMP4 Therapeutics | FY25 | 436.5% | −1,502.4% | −852.8% | — | — | — | |
| Marker Therapeutics | FY25 | −46.2% | −363.4% | — | — | — | — | Compare |
| CervoMed | FY25 | −58.9% | −706.2% | — | — | — | — | Compare |
| Upstream Bio | FY25 | 20.4% | −5,618.8% | −4,675.5% | — | — | — | Compare |
| Cartesian Therapeutics | FY25 | −92.8% | −5,127.1% | −2,838.6% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 0 | 1 | 4 |
| Revenue growth | — | 86.3% | 436.5% |
| Gross profit | — | — | — |
| Research and development | 41 | 39 | 38 |
| Operating income | −52 | −53 | −53 |
| Net income | −49 | −52 | −80 |
| Diluted EPS (US$) | −124.80 | −11.04 | −2.65 |
| Diluted shares (millions) | 0 | 5 | 30 |
| Cash flow | |||
| Cash from operations | −44 | −46 | −30 |
| Capital expenditure | 1 | 0 | 0 |
| Free cash flow | −45 | −46 | −30 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 4 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 38 | 64 | 110 |
| Debt incl. finance leases | — | — | — |
| Total assets | 55 | 78 | 118 |
| Total liabilities | 16 | 15 | 70 |
| Shareholders' equity | −124 | 63 | 48 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −14,822.6% | −8,142.3% | −1,502.4% |
| Net margin | −14,083.1% | −7,943.4% | −2,298.5% |
| Free cash flow margin | −12,809.4% | −7,055.7% | −852.8% |
| Rule of 40 (growth + FCF margin) | — | −6,969.4% | −416.3% |
| Return on capital | — | — | — |
| Return on equity | — | — | −145.1% |
| Return on assets | — | −77.7% | −82.0% |
| Net debt to EBITDA | — | — | — |